Clinical studies can provide us with information to help us to understand the levels of HPHCs a subject has been exposed to and about changes in the risk of developing smoking-related diseases when switching to one of our smoke-free products.

In order to assess if a product is likely to be acceptable to adult smokers, we also conduct Pharmacokinetics / Pharmacodynamics clinical studies.

Our clinical studies are published on the largest on-line repository of clinical studies, www.clinicaltrials.gov. Aligned with the practices of the pharmaceutical industry, the studies are conducted by experienced Contract Research Organizations (CROs) which conduct studies for various industries including the pharmaceutical industry. All of our clinical studies comply with the internationally recognized requirements of the International Conference of Harmonization’s Good Clinical Practice (ICH-GCP).

 

Markers of harmful compounds in participants’ samples were investigated in studies:

NCT01970982NCT01959932NCT01989156NCT01970995,

NCT02641587NCT02503254, NCT03550989.

 

Information about the risk of smoking-related diseases was collected in studies:

NCT02396381NCT02649556 and NCT02432729.

 

The long-term effects of smoke-free product use is being evaluated in: NCT03020667NCT03527030, NCT03527017 and NCT03527004.

 

In depth about our Clinical Assessment